MyFinsight
Home
Blog
About
Short-term investments
$6,652K
(22.73%↑ Y/Y)
Other current assets
$3,339K
(36.34%↑ Y/Y)
Cash and cash
equivalents
$3,221K
(-80.94%↓ Y/Y)
Accounts receivable
$318K
Total current assets
$13,530K
(-45.38%↓ Y/Y)
Operating lease assets
$6,688K
(-39.35%↓ Y/Y)
Other assets
$765K
(-17.48%↓ Y/Y)
Property and equipment,
net
$41K
(-76.70%↓ Y/Y)
Total assets
$21,024K
(-43.03%↓ Y/Y)
Accumulated deficit
-$2,030,844K
(-0.83%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$2K
Total liabilities and
stockholders' equity...
$21,024K
(-43.03%↓ Y/Y)
Total stockholders'
equity (deficit)
-$36,996K
(-5.58%↓ Y/Y)
Additional paid-in capital
$1,993,849K
(0.74%↑ Y/Y)
Common stock - 0.0001
par value, 500,000...
$1K
(0.00%↑ Y/Y)
Total liabilities
$58,020K
(-19.35%↓ Y/Y)
Liability related to the
sale of future...
$40,506K
(0.71%↑ Y/Y)
Operating lease
liabilities - long-term
$8,782K
(-43.07%↓ Y/Y)
Total current
liabilities
$6,847K
(-52.98%↓ Y/Y)
Other long-term
liabilities
$1,885K
(8.83%↑ Y/Y)
Other current
liabilities
$3,460K
(-54.90%↓ Y/Y)
Liability related to the
sale of future...
$1,032K
Accounts payable
$824K
(-53.23%↓ Y/Y)
Deferred revenue
$775K
(-51.77%↓ Y/Y)
Accrued compensation
$699K
(-72.61%↓ Y/Y)
Accrued research and
development expenses
$57K
(-94.13%↓ Y/Y)
Back
Back
Balance Sheet
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)
source: myfinsight.com